Evidence map›Paper›PMID 28242791›Full record

ArticleThe oncologist2017

Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and

Marc Wehrli, Elisabeth Oppliger Leibundgut, Heinrich H Gattiker, Markus G Manz, Antonia M S Müller, Jeroen S Goede

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Pharmacological and Biological Targeting of FGFR1 in Cancer.Current issues in molecular biology · 2024
    Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Marc WehrliDivision of Hematology, University Hospital Zurich, Zurich, Switzerland.
Elisabeth Oppliger LeibundgutDivision of Hematology, Inselspital University Hospital Bern, Bern, Switzerland.
Heinrich H GattikerSeefeldstrasse 45, 8008, Zurich, Switzerland.
Markus G ManzDivision of Hematology, University Hospital Zurich, Zurich, Switzerland.
Antonia M S MüllerDivision of Hematology, University Hospital Zurich, Zurich, Switzerland antoniamaria.mueller@usz.ch.
Jeroen S GoedeDivision of Hematology, University Hospital Zurich, Zurich, Switzerland.
University Hospital of Zurich · CHUniversity Hospital of Bern · CHZürich Airport (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with

Indexed as

Cell Cycle ProteinsChromosomes, Human, Pair 8DasatinibDown SyndromeFemaleHumansLeukemoid ReactionMiddle AgedNeoplasmsOncogene Proteins, FusionProtein Kinase InhibitorsQuality of LifeReceptor, Fibroblast Growth Factor, Type 1Translocation, GeneticCell Cycle ProteinsCNTRL protein, humanDasatinibFGFR1 protein, humanOncogene Proteins, FusionProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 1Acute myeloid leukemiaCEP110‐FGFR1 fusion proteinDasatinibEosinophiliaImatinib

Identifiers

PMID28242791
PMCPMC5388377
OpenAlexW2593339236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.